Neulasta (Pegfilgrastim)

Pegfilgrastim, the active ingredient in Neulasta, is a granulocyte colony‑stimulating factor (G‑CSF) analog presented as a 6 mg prefilled syringe for subcutaneous use. It is employed to reduce chemotherapy‑induced neutropenia in patients receiving myelosuppressive chemotherapy regimens.

GNH USA supplies Neulasta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides cold‑chain logistics for biologic products.

Neulasta (pegfilgrastim) supports the hematopoietic system in patients undergoing myelosuppressive chemotherapy, helping to maintain neutrophil counts.

- Prophylaxis of neutropenia: Reduces the incidence and duration of chemotherapy‑induced neutropenia in patients receiving myelosuppressive regimens. - Infection risk reduction: Lowers the risk of febrile infections in patients with non‑myeloid malignancies undergoing chemotherapy. - Peripheral blood progenitor cell mobilization: Facilitates collection of stem cells for autologous transplantation.

Pegfilgrastim may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Bone pain: aching discomfort in the limbs or back. - Injection site reactions: redness, swelling, or tenderness. - Headache: mild to moderate intensity. - Fatigue: feeling unusually tired. - Nausea: occasional upset stomach. - Fever: low‑grade temperature elevation.

Serious or Rare Side Effects: - Splenic rupture: sudden abdominal pain requiring emergency care. - Acute respiratory distress syndrome (ARDS): severe breathing difficulty. - Anaphylaxis: rapid onset of allergic reaction with hives, swelling, or airway compromise. - Capillary leak syndrome: hypotension and edema. - Severe allergic reaction: rash, itching, or swelling beyond the injection site.

Before initiating therapy, clinicians should consider patient‑specific factors and monitor for potential complications.

- Dose adjustment: Prescribe based on the patient’s chemotherapy regimen and neutrophil counts. - Pregnancy: Category C; use only if the potential benefit justifies the potential risk to the fetus. - Breastfeeding: Caution; pegfilgrastim may be present in breast milk. - Renal impairment: No dosage adjustment required, but monitor renal function. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Pegfilgrastim can interact with certain agents; awareness helps avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Concurrent use with other G‑CSF products. - Administration of live attenuated vaccines. - Overlapping myelosuppressive chemotherapy given within 24 h of pegfilgrastim.

Moderate Interactions (Monitor Closely): - High‑dose corticosteroids may diminish response. - Certain antibiotics (e.g., fluoroquinolones) that affect neutrophil function. - Antifungal agents that can alter pegfilgrastim clearance.